(Q40219504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

main subject

angiogenesis inhibitor

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Toshihiko Kuroda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Samuel D Rabkin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Andreas Kurtz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

6

Robert L Martuza

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Tingguo Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Hiroshi Fukuhara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Tomoki Todo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

1 reference

10 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

789-797

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Oncolytic viral therapies - the clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Recent progress in the battle between oncolytic viruses and tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Endogenous inhibitors of angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Clinical translation of angiogenesis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Platelet factor 4: an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Fibroblast Growth Factor Messenger Ribonucleic Acid Expression in a Human Astrocytoma Cell Line: Regulation by Serum and Cell Density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Elevated expression of basic fibroblast growth factor messenger ribonucleic acid in acoustic neuromas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Gene therapy strategies for tumor antiangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Mouse tumor model for neurofibromatosis type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.07.011

10.1016/J.YMTHE.2006.07.011

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045531%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference